Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 31, 2022

FLOT vs FLOT/Trastuzumab/Pertuzumab Perioperative Therapy for HER2-Positive Resectable Esophagogastric Adenocarcinoma

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group
J. Clin. Oncol 2022 Jun 16;[EPub Ahead of Print], RD Hofheinz, K Merx, GM Haag, C Springfeld, T Ettrich, K Borchert, A Kretzschmar, C Teschendorf, G Siegler, MP Ebert, E Goekkurt, R Mahlberg, N Homann, D Pink, W Bechstein, P Reichardt, H Flach, T Gaiser, A Battmann, FS Oduncu, M Loose, D Sookthai, C Pauligk, TO Göetze, SE Al-Batran

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading